Antibody persistence 2 and 3 years after booster vaccination of adolescents with recombinant acellular pertussis monovalent aP<sub>gen</sub> or combined TdaP<sub>gen</sub> vaccines.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 34386749.
- Also identified by DOI 10.1016/j.eclinm.2021.100976 and PMC identifier 8343263.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Recombinant pertussis vaccines inducing long-lasting immune responses could help to control the rise in pertussis. We here report on persisting antibody responses 2 and 3 years after booster vaccination with a new generation recombinant acellular pertussis vaccine. Participants of a phase 2/3 randomised-controlled clinical trial with a monovalent pertussis vaccine containing genetically inactivated pertussis toxin (aP<sub>gen</sub>) or its tetanus and diphtheria toxoids combination (TdaP<sub>gen</sub>), or a chemically detoxified comparator vaccine (Tdap<sub>chem</sub>), (originally conducted between July and August 2015) were invited to participate in observational studies of persisting antibody responses 2 and 3 years after vaccination. Serum IgG against pertussis toxin (PT-IgG) and filamentous hemagglutinin (FHA-IgG) were assessed by ELISA, and PT-neutralising antibodies (PT-Nab) by Chinese Hamster Ovary cell assay. Waning of antibodies stabilised in aP<sub>gen</sub> and TdaP<sub>gen</sub> vaccinees 2 and 3 years after vaccination. Three years post-vaccination PT-neutralising antibodies remained 4·6-fold (95% Confidence Interval (CI) 2·6-8·1) and 3·7-fold (95% CI 2·2-6·1) higher, PT-IgG antibodies 3·0-fold (95% CI 2·2-4·1) and 2·5-fold (95% CI 1·9-3·3) higher, and FHA-IgG antibodies 1·8-fold (95% CI 1·3-2·5) and 1·6-fold (95% CI 1·2-2·1) higher than baseline in aP<sub>gen</sub> and TdaP<sub>gen</sub> recipients, respectively. In the Tdap<sub>chem</sub> group, PT-neutralising and PT-IgG and FHA-IgG antibodies were back at baseline levels 2 years post-vaccination. Three years post-vaccination seroconversion rates for PT-neutralising antibodies were 65·0% (95% CI 44·1-85·9) and 55·0% (95% CI 33·2-76·8) in aP<sub>gen</sub> and TdaP<sub>gen</sub> recipients, respectively. Considering the persistence of elevated antibody responses 3 years post-booster vaccination, genetically detoxified monovalent aP<sub>gen</sub> and TdaP<sub>gen</sub> vaccines can be expected to induce longer-lasting protection than chemically inactivated Tdap vaccines. BioNet-Asia.